SummaryThe World Health Organization has issued draft guidelines recommending weight-loss drugs, such as GLP-1 therapies, for adults with obesity (BMI 30+). The move recognizes obesity as a chronic disease, not just a lifestyle issue. While promising, high drug costs limit access, especially in low- and middle-income countries. Final guidance is pending consultation.